Although high brain and acute leukemia, cytoplasmic (BAALC) expression is a well-characterized poor prognostic factor in acute myeloid leukemia (AML), neither the exact mechanisms by which BAALC drives leukemogenesis and drug resistance nor therapeutic approaches against BAALC-high AML have been properly elucidated. In this study, we found that BAALC induced cellcycle progression of leukemia cells by sustaining extracellular signal-regulated kinase (ERK) activity through an interaction with a scaffold protein MEK kinase-1 (MEKK1), which inhibits the interaction between ERK and MAP kinase phosphatase 3 (MKP3/DUSP6). BAALC conferred chemoresistance in AML cells by upregulating ATP-binding cassette proteins in an ERK-dependent manner, which can be therapeutically targeted by MEK inhibitor. We also demonstrated that BAALC blocks ERK-mediated monocytic differentiation of AML cells by trapping Krüppel-like factor 4 (KLF4) in the cytoplasm and inhibiting its function in the nucleus. Consequently, MEK inhibition therapy synergizes with KLF4 induction and is highly effective against BAALC-high AML cells both in vitro and in vivo. Our data provide a molecular basis for the role of BAALC in regulating proliferation and differentiation of AML cells and highlight the unique dual function of BAALC as an attractive therapeutic target against BAALC-high AML.
INTRODUCTION
Acute myeloid leukemia (AML) is a clonal disorder characterized by differentiation arrest and accumulation of immature myeloid progenitors in the bone marrow, resulting in hematopoietic failure. To date, several poor prognostic factors for AML have been reported, which include gene mutations in TET2, ASXL1 or DNMT3A and overexpression of ERG, EVI1, MN1 or BAALC. 1 In general, overexpression of BAALC is observed in one-fourth of AML patients, 2, 3 and recent reports have shown its adverse impact on the survival of AML patients across all karyotypes. 4 BAALC encodes at least eight alternatively spliced transcripts in humans, and BAALC 1-6-8 is the major isoform expressed in hematopoietic cells. 5 In normal hematopoiesis, the expression of BAALC is limited to the immature fraction, that is, CD34 + fraction rich in hematopoietic stem and progenitor cells. 6 In a large cohort of patients with AML, high BAALC expression is associated with expressions of stem cell markers. 2 From these facts, it is suggested that BAALC is related to immaturity of hematopoietic cells, but the precise function of BAALC in leukemogenesis is poorly understood.
Aberrant activation of several oncogenic signaling cascades is implicated in AML pathogenesis. 7 Previous reports showed that Ras/Raf/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway is activated in a significant proportion of AML patients and expected as a potential therapeutic target. 8 However, the anti-leukemic activity of MEK inhibitor monotherapy in the clinical settings has been modest, 9 which necessitates further elucidation of the networks of signaling molecules in this pathway. Among them, mitogen-activated protein kinase kinase kinase 1 (MEKK1) is a well-known kinase as well as a scaffold protein of key elements in ERK pathway. 10 Previous reports have suggested a fundamental role of MEKK1 in anti-apoptotic function in myeloid cells and leukemogenesis. 11, 12 By contrast, ERK can trigger tumor suppressor pathways as well, such as cellular senescence, apoptosis and differentiation in a context-dependent manner. 13, 14 Krüppel-like factor 4 (KLF4), a member of Krüppel-like family transcription factors, is induced by ERK activation and mediates growth inhibition in human colon cancer cells. 15 Although KLF4 has been shown to enhance stem-cell like properties as one of four iPS factors, it has been drawing attention in AML as an essential factor for monocytic differentiation. 16 In this study, we aimed to investigate the molecular basis of BAALC in leukemia cell proliferation. We demonstrate here that through interactions with MEKK1 and KLF4, BAALC potentiates oncogenic ERK pathway while inhibiting ERK-dependent differentiation. This study could also determine whether concurrent MEK inhibition and KLF4 induction would be a legitimate therapeutic modality for BAALC-high AML.
MATERIALS AND METHODS

Analysis of protein phosphorylation
AML cells transduced with BAALC or control vectors were stimulated by phorbol myristate acetate (PMA) at 100 ng/ml for 6 h, and then were harvested. After subsequent protein extraction, phosphorylation of signaling molecules was examined by immunoblotting.
Time-lapse immunoprecipitation assay AML cells transduced with BAALC or control vectors were starved for 24 h, then stimulated by PMA at 100 ng/ml for the indicated time periods. After subsequent cell lysis, extracted proteins were immunoprecipitated by anti-MYC-tag antibody or anti-ERK antibody with sepharose G protein beads. Protein-protein interaction was examined by immunoblotting.
Immunoblotting
Immunoblotting was performed as previously described. 17 See Supplementary methods for details.
Yeast two-hybrid screening
Yeast two-hybrid screening was performed with the Matchmaker Gold Yeast Two-Hybrid System (Clontech, Mountain View, CA, USA). Human BAALC 1-6-8 cDNA was used as a bait and cloned into the pGBKT7 vector in frame with the GAL4 DNA-binding domain (pBD-BAALC). Yeast Y2H GOLD cells were then co-transformed with pBD-BAALC, SmaI-linearized prey vector (pGADT7) and a cDNA library generated from healthy human bone marrow. Interaction was confirmed as described in the Yeast Protocol Handbook (Clontech). After extraction of plasmids from positive clones, inserted cDNA was sequenced by 3130 × L Genetic Analyzer (Applied Biosystems, Waltham, MA, USA) and identical aliment was computationally searched by BLAST (Basic Local Alignment Search Tool, National Library of Medicine).
Mice NOD/SCID/gamma (NSG) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Littermates were used as controls in all experiments.
Xenograft mouse model
Xenograft mouse model of human AML with high expression of BAALC was developed using NSG mice. Before transplantation, NSG mouse was treated with intraperitoneal injection of cyclophosphamide 100 mg/kg/day for 2 days. At day 0 and day 1, 5 × 10 6 cells/body of Kasumi-1 cells transduced with indicated viruses were intravenously injected. Peripheral blood was collected twice a week and chimerism was checked by flow cytometer. Once peripheral blood chimerism of leukemia cells exceeded 1%, treatment either by U0126 (25 μmol/kg/week intraperitoneally) or by doxycycline (diluted in drinking water at 1 mg/ml+3% sucrose) was started.
See Supplementary methods for more information.
RESULTS
BAALC promotes leukemia cell expansion
We first examined the expression levels of BAALC in primary human bone marrow samples from AML patients and control subjects as well as in seven AML cell lines. AML cells showed about 10-fold higher BAALC than control subjects ( Figure 1a ). BAALC was higher even in human primitive CD34 + CD38 − AML cells compared with normal CD34 + CD38 − cells rich in hematopoietic progenitor cells (Supplementary Figure S1A ). Among seven AML cell lines, Kasumi-1 and OCI-AML2 showed comparable BAALC levels as BAALC-high AML patient samples, while BAALC expressions were low in HEL and MV4-11. From this finding, hereafter we used Kasumi-1 and OCI-AML2 as BAALC-high leukemia cells, and HEL and MV4-11 as BAALC-low cells (Figures 1a and b ). When fulllength of BAALC (1-6-8 form) was lentivirally transduced to HEL and MV4-11 cells, they showed increased proliferative capacity and accelerated cell-cycle progression, while apoptotic status was not altered (Figure 1c ; Supplementary Figures S1C and F). On the other hand, BAALC-knocked down Kasumi-1 and OCI-AML2 cells by retroviral short hairpin RNA (shRNA) showed opposite phenotype to BAALC overexpression. Moreover, phenotypes associated with BAALC knockdown were completely rescued by additional expression of shRNA-resistant cDNA construct of BAALC (Figure 1d ; Supplementary Figures S2A and C and S3A and C).
These results indicate that BAALC promotes proliferation, cellcycle progression of leukemia cells along with inhibition of leukemia cell differentiation.
MEKK1 and KLF4 are novel interacting partners of BAALC To gain insight into molecular functions of BAALC, interacting partners of BAALC were explored with a yeast two-hybrid system on a proteome-wide scale (Supplementary Figure S4A ). Using BAALC as a bait and a cDNA library from adult human tissues as prey, we identified eight possible interacting molecules ( Figure 1e ). Among them, we focused on MEKK1 and KLF4, both of which are known to have substantial roles in Ras/Raf/MEK/ERK pathway, one of pivotal oncogenic signaling cascades in AML. 10, 18 To validate the interactions between BAALC and MEKK1 or KLF4, we performed CoIP assay in AML cells. Intriguingly, BAALC bound to MEKK1 more tightly in the presence of PMA, a potent activator of multiple cytoplasmic signal transduction cascades, while BAALC-KLF4 complex was formed independently of PMA stimulation ( Supplementary Figures S4B and E ). Protein-protein interactions between BAALC and MEKK1 or KLF4 were further affirmed by in vitro pull-down assays using purified proteins from mammalian cells (Figures 1f and g) . These results illustrate that BAALC directly interact with MEKK1 in a stimulation-dependent, and with KLF4 in a stimulation-independent manner.
N-terminal region of BAALC is necessary and sufficient for the interactions with MEKK1 and KLF4
Next, we elucidated an essential binding region of each protein using a series of deletion mutants of BAALC, MEKK1 and KLF4. CoIP assay revealed that N-terminal region of BAALC (amino acids 1-35) was an indispensable prerequisite for its binding to MEKK1 and KLF4 ( Supplementary Figures S5A and B ). Notably, this N-terminal region of BAALC is conserved across all mammals expressing BAALC, indicating the functional importance of this region. 5 HEL cells expressing deletion mutants of BAALC harboring N-terminal 1-35 amino-acid sequence (Δ1, Δ2) showed comparable proliferation and cell-cycle progression (Supplementary Figures S5C and E) to cells expressing full-length BAALC. By contrast, BAALC mutants lacking N-terminal domain (Δ3, Δ4) had no effect on proliferation and cellcycle progression, underscoring a fundamental role of this region for proliferative capacity of BAALC. Furthermore, we found that C-terminal region of MEKK1 and KLF4 was necessary for their interactions with BAALC ( Supplementary Figures S6A and B) . These findings indicate that the N-terminal region of BAALC is essential for cell-cycle progression of myeloid leukemia cells through interactions with C-terminal regions of MEKK1 and KLF4.
BAALC prolongs ERK activation by inhibiting reassociation of an ERK-specific phosphatase MAP kinase phosphatase 3
Considering that both MEKK1 and KLF4 are involved in ERK pathway, we postulated that BAALC induces leukemia cell proliferation by potentiating MEK/ERK signaling. By BAALC overexpressions in BAALC-low AML cells, we found that BAALC specifically upregulated the activities of ERK and its direct downstream target ribosomal protein S6 kinase, 90 kDa (p90RSK), without affecting the phosphorylation status of other upstream molecules of ERK (Figure 2a ). The activities of other signaling pathways including PI3K-AKT, JAK-STAT and NF-κB pathways were not altered by BAALC ( Supplementary Figure S7A ), suggesting that BAALC specifically affects the activity of ERK. Similarly, AML cells transduced with BAALC showed prolonged ERK activation compared with the control (Figure 2b ; Supplementary Figures S7B and C) . Consistent with these findings, knockdown of BAALC in AML cells had decreased ERK activation, which was reverted by additional expression of BAALC (Supplementary Figure S8A ).
As shown above, BAALC potentiated ERK phosphorylation without influencing upstream kinase activity of ERK, although BAALC has no known kinase or phosphatase sequence motifs. 6 We thus hypothesized that BAALC contributes to the sustained ERK phosphorylation by hindering the interaction between ERK and mitogen-activated protein kinase phosphatase 3 (MKP3/DUSP6), an ERK-specific phosphatase that mediates deactivation of ERK signaling. 19 To test this hypothesis, we conducted a time lapse analysis of CoIP assay, in which AML cells overexpressing BAALC were harvested at the indicated time points after stimulation and analyzed for the interaction between BAALC, ERK, MKP3 and MEKK1. BAALC bound to MEKK1 immediately after PMA stimulation, strongest at around 3-6 h after stimulation (Figure 2c ; Supplementary Figures S8B and C) . As for the interaction between ERK and MKP3, PMA treatment rapidly induced dissociation of MKP3 from ERK, followed by MKP3 reassociation with ERK after 6 h of stimulation in control cells. On the contrary, in BAALCoverexpressing cells, the recruitment of MKP3 to ERK at 6 h was hindered along with the stimulation-dependent BAALC-MEKK1 interaction up to 9 h after stimulation (Figure 2d ; Supplementary  Figures S8D and E) . The extent of ERK phosphorylation was inversely correlated to the intensity of ERK-MKP3 interaction, underscoring the importance of MKP3 in ERK activity (Figure 2b ; Supplementary Figures S7B and C) .
BAALC induces drug resistance in AML cells through ERK activation
To further investigate the specificity and oncogenic potentiality of BAALC in ERK pathway, we treated BAALC-or control vectortransduced AML cells by various signaling inhibitors and examined their proliferation. Both genetic and pharmacologic inhibition of ERK pathway completely abrogated the growth advantage conferred by BAALC, which were not observed by inhibiting other signaling pathways ( Supplementary Figures S9A, B and S10A). Growth advantage of BAALC-expressing cells was also reversed by forced expression of MKP3 (Supplementary Figures S11A and C), suggesting that BAALC affects proliferative capacity of AML cells in an ERK-dependent manner. These results collectively indicate that BAALC interacts directly with MEKK1, an essential scaffold protein for ERK activation, and prolongs ERK activation by inhibiting reassociation of MKP3 to ERK (Supplementary Figure S11D) .
High BAALC expression is clinically associated with overexpression of genes involved in drug resistance, lower complete remission rate and refractoriness to chemotherapy in AML cases. 2, 20 Given that ERK can exert its oncogenic activity through increased resistance to chemotherapeutic drugs, 21 we deduced that BAALC leads to drug resistance via ERK pathway. ATP-binding cassette (ABC) superfamily represents a major mechanism of drug resistance, 22 and among them, ABCB1 (MDR1; multidrug resistance protein 1) and ABCG2 (BCRP1; breast cancer resistance protein 1) are well-known downstream targets of ERK pathway. [23] [24] [25] We then treated AML cells with cytosine arabinoside (AraC), an essential component of AML treatment, and measured the mRNA expression of these ABC transporters. Additive BAALC expression in AML cells potentiated the upregulation of these genes in response to AraC treatment. This upregulation was selectively abrogated by ERK pathway inhibition (Figure 2e ; Supplementary Figure S12A ), indicating that BAALCinduced drug resistance is dependent on MEK/ERK pathway. When the half-maximal inhibitory concentrations (IC 50 ) were assessed, in line with the high expression of resistance-related genes, BAALC-expressing cells were more resistant to AraC treatment, of which were again specifically overcome by ERK pathway inhibition (Figure 2f; Supplementary Figure S13A ). These results support the idea that BAALC induces drug resistance by upregulating drug resistance genes in an ERK-dependent way, which can be targeted by MEK inhibitor.
Nuclear KLF4 drives monocytic differentiation by constitutive activation of ERK pathway To address whether the growth-promoting effect of BAALC overexpression on leukemia cells is dependent on the ERK pathway, the constitutive active form of MEK1 (CA-MEK1, S218E/S222E) was transduced into BAALC-low AML cells. In clear contrast to the case of BAALC overexpression, CA-MEK1 decreased cell proliferation and induced monocytic differentiation, despite the comparable phosphorylation of ERK to BAALC (Figures 3a and b ; Supplementary  Figures S14A and C) . To further investigate this phenotypic discrepancy, we focused on a biological function of KLF4, one of the other interacting partners of BAALC. The expression of KLF4 is positively regulated by ERK in tumor cells from several origins, 15, 26 and it is considered to be involved in monocytic differentiation of myeloid cells. 16 When we compared the expression levels of KLF4 by immunoblotting, nuclear expression of KLF4 was increased in CA-MEK1-transduced AML cells, accompanied by an increase of KLF4 in whole-cell lysates. When KLF4 was knocked down by shRNA in this context, CA-MEK1-induced growth arrest was reversed along with decreased KLF4 expression in the nucleus, although knockdown of KLF4 had little effect on the proliferative capacity in the absence of constitutive activation of ERK (Figure 3c ; Supplementary Figures S15A and B) . CA-MEK1-induced differentiation was also counteracted by KLF4 depletion assessed by surface expression of monocyte differentiation markers and microscopic morphology ( Supplementary Figures S15C and D) . These data indicate that sustained activation of ERK pathway induces monocytic differentiation in leukemia cells in a KLF4dependent manner.
BAALC antagonizes KLF4 activity through ERK activation and inhibition of nuclear KLF4 translocation
We next explored the physiological significance of interplay between BAALC and KLF4. When BAALC was transduced to AML cells, KLF4 translocated from the nucleus to the cytoplasm (Figure 3d ; Supplementary Figures S16A and D) . On the contrary, knockdown of BAALC led to KLF4 shift from the cytoplasm to the nucleus (Figure 3e ; Supplementary Figures S17A and D) . When CD34 + CD38 − bone marrow cells from AML patients were assessed for KLF4 localization, BAALC-high cases (the upper quartile of BAALC expression) mainly showed cytoplasmic KLF4, while KLF4 was proportionally distributed both in the nucleus and in the cytoplasm in BAALC-low cases (the lower quartile) (Figure 3f ; Supplementary Figure S17E ). These data indicate that BAALC reduces the amount of nuclear KLF4 by nucleo-cytoplasmic translocation.
To prove the hypothesis that BAALC inhibits ERK-mediated monocytic differentiation by relocating KLF4 from the nucleus to the cytoplasm, we examined the effect of additional BAALC expression on proliferation and differentiation of CA-MEK1expressing cells. BAALC overexpression in CA-MEK1-transduced AML cells restored proliferative capacity (Supplementary Figure S18A) . CA-MEK1-expressing cells with simultaneous BAALC expression were resistant to CA-MEK1-induced differentiation ( Supplementary  Figures S18B and D) . The amount of nuclear KLF4 was reduced by Figure S6A ). Purified MYC-tagged BAALC and HA-tagged MEKK1-Δ4 proteins were mixed and immunoprecipitated by anti-MYC tag antibody followed by blotting with anti-HA tag antibody. (g) Interaction between BAALC and KLF4 by in vitro pull-down assay. To obtain soluble recombinant protein, shortened form of KLF4 (KLF4-Δ2) was utilized (see Supplementary Figure S6B ). Purified MYC-tagged BAALC and His-tagged KLF4-Δ2 proteins were mixed and immunoprecipitated by anti-MYC tag antibody followed by blotting with anti-His tag antibody. Data are mean ± s.e.m. values. *Po0.05, **Po0.01. Figure S18E) , supporting the hypothesis that BAALC blocks ERK-dependent differentiation by affecting the amount of KLF4 in the nucleus.
BAALC in CA-MEK1-expressing cells (Supplementary
To further elucidate the role of KLF4 in BAALC-derived proliferation and differentiation block with prolonged ERK activation, we assessed the effect of additional KLF4 expression on BAALC-expressing cells. As expected, KLF4 overexpression restored nuclear KLF4 and abrogated the differentiation block by BAALC ( Supplementary Figures S19A and E) . Furthermore, mRNA expressions of key regulators in cell-cycle progression positively regulated by ERK, such as cyclin-dependent kinase 6 (CDK6) and cyclin D1 (CCND1), 27 were consistently increased in BAALC-overexpressing AML cells and decreased by BAALC knocking down. Meanwhile, the expression of cyclin-dependent kinase inhibitor 1 (CDKN1A, p21) , an essential factor for KLF4-mediated tumor suppression as a major transactivation target of KLF4, 28 was decreased in BAALC-overexpressing AML cells and increased in BAALC-knocked down cells ( Supplementary Figures S20A and B) . These findings collectively indicate that BAALC promotes cell-cycle progression by activating ERK pathway, and inhibits monocytic differentiation by inhibiting nuclear translocation of KLF4.
MEK/ERK inhibition in combination with KLF4 induction is a potential therapeutic strategy against BAALC-high AML From the above-mentioned data, it is suggested that modulating ERK pathway and KLF4 expression would be effective for treating BAALC-high leukemia. Thus, we established tetracycline-inducible (Tet-ON) KLF4-expressing AML cell lines, in which KLF4 is induced by doxycycline. Given that BAALC exerts dual actions on leukemia cells through ERK and KLF4, we evaluated the combination therapy by MEK inhibition and KLF4 induction in Kasumi-1 cells and BAALC-overexpressing HEL cells. Of note, there was an inhibitory effect of MEK inhibition and KLF4 induction on cell proliferation, possibly reflecting accelerated differentiation induced by KLF4 ( Supplementary Figures S21A-C) .
We next assessed the effect of MEK inhibition on the proliferation of several AML cell lines. Interestingly, sensitivity to MEK inhibitor was positively correlated to BAALC expression level ( Figure 4a ). The concentration of U0126 to inhibit the proliferation of AML cell lines with high BAALC (Kasumi-1, OCI-AML2) was 1/15 to 1/25 of that, when compared to cells with low BAALC (MV4-11, HEL) (Supplementary Figure S21D) . BAALC expression was also positively correlated to in vitro sensitivity to U0126 among primary human AML cells (Figure 4b ), highlighting MEK/ERK pathway as a legitimate therapeutic target in AML with high BAALC expression.
Finally, we developed BAALC-high AML model mice using NSG mouse to investigate the combinational effect of MEK inhibition and KLF4 induction in vivo (Figure 4c ), by transplanting Kasumi-1 cells expressing either BAALC shRNA or control shRNA as well as by transplanting HEL cells expressing either BAALC or control vector. These xenotransplants succumbed to AML characterized by extensive infiltration of human CD45 + leukemia cells in the BM, the liver and the spleen ( Supplementary Figures S22A and B) . BAALC shRNA had a positive effect on mice transplanted with Kasumi-1 cells to prolong their survival, and exogenous BAALC had a negative effect on those transplanted with HEL cells, recapitulating the adverse prognostic impact of high BAALC expression in human AML ( Supplementary Figures S23A and B ). Next, we transplanted these BAALC-high AML cells transduced with lentiviral Tet-ON vector encoding KLF4 into NSG mice. After confirming the engraftment of AML cells in peripheral blood by flow cytometry, we divided engrafted mice into four groups; control group, U0126 monotherapy group, doxycycline monotherapy group, and U0126 plus doxycycline combination therapy group. Compared with the modest effect of MEK inhibition or KLF4 induction monotherapy on overall survival, MEK inhibition plus KLF4 induction significantly prolonged the survival (Figures 4d and e ). By contrast, MEK inhibitor with or without KLF4 induction therapy exerted smaller impact on the survival of NSG mice engrafted with low BAALC-expressing HEL cells, compared with the cases of high BAALC-expressing AML cells (Supplementary Figure S23C) , underscoring the importance of these pathways in the maintenance of BAALC-high AML cells. Overall, these findings clearly indicate that MEK inhibition combined with KLF4 induction would be a promising therapeutic strategy against BAALC-high AML (Figure 4f ).
DISCUSSION
In this study, we showed that BAALC promotes proliferation and drug resistance of AML cells by sustained activation of ERK pathway through the interaction with MEKK1 and that BAALC inhibits monocytic differentiation induced by ERK through nucleocytoplasmic translocation of KLF4. We also demonstrated that inhibition of ERK pathway, especially combined with KLF4 induction, is highly effective against BAALC-high leukemia cells both in vitro and in vivo.
Our detailed experiments revealed that BAALC interacts with MEKK1, inhibits reassociation of ERK and MKP3, and consequently maintains ERK activity. Sustained activation of ERK pathway promotes proliferation through cell-cycle progression in AML cells. In addition, ERK-dependent upregulation of chemoresistance-associated transporters in response to cytotoxic agents was enhanced by BAALC overexpression, indicating that BAALC mediates a variety of functions on AML cells by modulating ERK activity. Considering the association of higher BAALC expression among AML patients and paucity of promising drugs in clinical use targeting these transporters, the rationality of treating BAALC-high AML with MEK inhibitors to overcome ERKmediated drug resistance should be emphasized.
Although aberrant activation of ERK pathway is implicated in the biology of AML, 7 chronic activation of ERK induced by constitutive active form of MEK1 leads AML cells to monocytic differentiation. 29 In this report, we demonstrated that this differentiation of AML cells depends on KLF4 induction, which is one of the other interacting partners of BAALC. In addition, we showed that BAALC inhibits the nuclear localization of KLF4 by interacting with KLF4 in cytoplasm. To our knowledge, this is the first report to show that cytoplasmic sequestration of KLF4 confers oncogenic potential. Our study also suggests that targeting KLF4 would be a rational choice for overcoming treatment-resistant BAALC-high AML.
Furthermore, our data indicated that MEK inhibition could effectively treat BAALC-high AML. Although several MEK inhibitors are already utilized in a clinical setting, the efficacy of MEK inhibitor monotherapy is limited so far, first because of the high probability of side effects due to its narrow therapeutic concentration range. 30 In our experiments using AML cell lines and primary human samples, AML cells with higher expression of BAALC possessed higher sensitivity to MEK inhibitor U0126. In addition, U0126 decreased the proliferation rate of leukemia cells with high BAALC expression at significantly lower concentration compared with that of BAALC-low cells. These results suggested that AML patients with higher expression of BAALC might be effectively treated by MEK inhibitor at relatively low doses to reduce its toxicity. Moreover, MEK inhibitor can reverse the drug resistance conferred by BAALC, which might be involved in unfavorable prognosis of BAALC-high AML patients, and can potentiate the therapeutic efficacy of other antileukemic agents. Given that U0126 cannot reverse differentiation block caused by direct interaction of BAALC with KLF4 independently from ERK, KLF4 induction therapy both in vitro and in vivo was combined with MEK inhibition in this study. Our results clearly showed that concurrent MEK inhibition and KLF4 induction are highly effective for BAALC-high AML. Several drugs that can induce KLF4 have been evaluated in clinical and preclinical settings, making our approach feasible and highly promising. 31 To date, there have been few reports that provide a perspective on the leukemogenic property of BAALC itself. [32] [33] [34] [35] Actually, our overexpression and knockdown study revealed the significance of BAALC as an unprecedented dual-acting protein, which functions as an adaptor protein in MAPK cascade and as a molecular trap against KLF4 in the cytoplasm, but this property of BAALC should be elucidated by using antibodies that can detect endogenous BAALC in the future. Considering that MEK inhibition is effective for BAALC-high leukemia cells even at low doses and concurrent KLF4 induction further enhances therapeutic efficacy, our results strongly indicate that combination therapy targeting this novel BAALC-ERK-KLF4 axis would become a promising strategy for refractory AML with high BAALC expression.
